Lapsed Jun 20, 2025 on the fee record · High confidence
20-year base term ends Nov 10, 2029
Second maintenance fee unpaid; grace period ended.
Held by Arbutus Biopharma Corporation
Filed Feb 24, 2015 as application 14/629,991 · Granted Jun 20, 2017
Base term, 20 years from filing
Today
Lapsed Jun 20, 2025
2009
2029
Clock starts
Nov 10, 2009
Nov 10, 2009
No longer in force
Jun 20, 2025
Jun 20, 2025
Granted
Jun 20, 2017
Jun 20, 2017
Term would have run to
Nov 10, 2029
Nov 10, 2029
base term
after the term ends
fee events
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,999,351, to Nov 10, 2029. The term already ends on or before that date, so the cap shortened nothing.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
Its term would have run to Nov 10, 2029: its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 10, 2009, when application PCT/US2009/063931, the earliest non-provisional in its chain, was filed (this one was filed Feb 24, 2015) | Nov 10, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,999,351) | resolves to Nov 10, 2029, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | lapsed Jun 20, 2025 | High confidence |
| Computed term end | The steps above, in order | Jun 20, 2025 | High confidence |
This family
| Application PCT/US2009/063931 | PCT application no patent term | no patent term |
| US 8,999,351 | In force Nov 2030 | Nov 2030 |
| US 9,682,139 | this patent Jun 2025 | Jun 2025 |
| US 10,117,941 | Grace period ended Nov 2029 | Nov 2029 |
| US 10,821,186 | In force Nov 2029 | Nov 2029 |
| Application 17/065,208 | Abandoned not computed | not computed |
| Application 18/110,791 | Abandoned not computed | not computed |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 27, 2016 Reel 40154, frame 419 | Tekmira Pharmaceuticals Corporation | Arbutus Biopharma Corporation | Change of Name |
| Nov 2, 2016 Reel 40198, frame 691 | Manoharan, Muthiah; Rajeev, Kallanthottathil G.; Jayaraman, Muthusamy; Narayanannair, Jayaprakash K.; Maier, Martin; Butler, David; Eltepu, Laxman | Alnylam Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Nov 2, 2016 Reel 40198, frame 798 | Alnylam Pharmaceuticals, Inc. | Tekmira Pharmaceuticals Corporation | Assignment of Assignor's Interest |
| Jul 27, 2018 Reel 46640, frame 764 | Protiva Biotherapeutics Inc.; Arbutus Biopharma Corporation | Arbutus Biopharma Corporation | Merger and Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 8,999,351, ends no earlier than this term, so it caps nothing.
Citations
114
later US patents cite this one
That is top 5% of utility patents granted in 2017 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.